Potential contribution of action of renin angiotensin system to bone metabolism

Current Hypertension Reviews

Volumn 3, Issue 2, 2007, Pages 129-132

  Nakagami, Hironori ^a   Osaka, Mariana Kiomy ^a   Shimizu, Hideo ^a   Hanayama, Rie ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Antihypertensive; Bone mineral density; Osteoporosis; Parathyroid hormone; Systolic blood pressure

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HORMONE; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; INTERLEUKIN 1; LOSARTAN; MOEXIPRIL; QUINAPRIL; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

AUTOCRINE EFFECT; BONE DEVELOPMENT; BONE MARROW; BONE MATURATION; BONE METABOLISM; BONE REMODELING; CALCIUM METABOLISM; CAPILLARY FLOW; CELL ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FRACTURE; HUMAN; HYPERTENSION; IN VITRO STUDY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

EID: 34248666447     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340207780598428     Document Type: Review

References (33)

1. Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. BMJ 1991; 303: 453-9.
2. Mancini M, Ferrara AL, Strazzullo P, Marotta T. Metabolic disturbances and antihypertensive therapy. J Hypertens Suppl 1991; 9: S47-50.
3. MacGregor GA, Cappuccio FP. The kidney and essential hypertension: a link to osteoporosis? J Hypertens 1993; 11: 781-5.
4. McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M, Krutzik S. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension 1980; 2: 162-8.
5. Young EW, McCarron DA, Morris CD. Calcium regulating hormones in essential hypertension. Importance of gender. Am J Hypertens 1990; 3: 161S-166S.
6. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 1999; 354: 971-5.
7. Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens 2001;14: 704-7.
8. Duarte CG, Winnacker JL, Becker KL, Pace A. Thiazide-induced hypercalcemia. N Engl J Med 1971; 284: 828-30.
9. Ma YF, Stimpel M, Liang H, Pun S, Jee WS. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol 1997; 154: 467-74.
10. Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group.Ann Intern Med 1993; 118: 666-73.
11. Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 1995; 10: 106-11.
12. Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture.Ann Intern Med 2003; 16: 476-82.
13. Wasnich R, Davis J, Ross P, Vogel J. Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 1990; 301: 1303-5.
14. Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Home AM, Evans MC, Murray MA, McNeil AR, Gamble GD. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000; 109: 362-70.
15. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 133: 516-26.
16. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC; Geelong Osteoporosis Study. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004;19: 19-24.
17. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004; 292: 1326-32.
18. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 1992; 152: 5-10.
19. Hiruma Y, Inoue A, Hirose S, Hagiwara H. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun 1997; 230: 176-8.
20. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
21. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Nail Acad Sci USA 1998; 95: 3597-602.
22. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
23. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97: 1566-71.
24. Jimi E, Nakamura I, Duong LT, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999; 247: 84-93.
25. van der Pluijm G, Most W, van der Wee-Pals L, de Groot H, Papapoulos S, Lowik C. Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 1991; 129: 1596-1604.
26. Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab 1992; 75: 988-92.
27. Puig JG, Mateos FA, Ramos TH, Lavilla MP, Capitan MC, Gil A. Albumin excretion rate and metabolic modifications in patients with essential hypertension. Effects of two angiotensin converting enzyme inhibitors. Am J Hypertens 1994; 7: 46-51.
28. Perez-Castrillon JL, Justo I, Silva J, et al. Relationship between bone mineral density and angiotensin converting enzyme polymorphism in hypertensive postmenopausal women. Am J Hypertens 2003; 16: 233-5.
29. Broutik PD, Tesar V, Zima T, Jirsa M. Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res; 2001; 50: 353-8.
30. Ma YF, Stimpel M, Liang H, Pun S, Jee WS. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol 1997; 154: 467-74.
31. Perez-Castrillon JL, Silva J, Justo I, et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 2003; 16: 453-9.
32. Lynn H, Kwok T, Wong SYS, Woo J, Leung PC. Angiotensin converting enzyme inhibitior use is associated with higher bone mineral density in elderly Chinese. Bone 2006; 38: 584-8.
33. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-9.